LY248686 is an inhibitor of serotonin (S-hydroxytryptamine; 5-HT) and norepinephrine (NE) uptake in synaptosomal preparations of hypothalamus and cerebral cortex, and 5-HT uptake in human blood platelets, with inhibitor constants near nanomolar concentrations. Upon administration to rats 1 hour before sacrifi ce, LY248686 caused dose-dependent and parallel decreases of 5-HT and NE uptake in hypothalamus homogenates ex vivo. LY248686 is a positive enantiomer and was slightly more potent than its negative isomer, LY248685, as an inhibitor of 5-HT uptake. Both isomers were only weak inhibitors of dopamine (DA) uptake in striatal synaptosomes. The inhibitory effects on 5-HT and NE uptake after a single administration of LY248686 KEY WORDS: Uptake; Inhibitor; Serotonin; Norepineph rine
of NE uptake (Richelson 1987; Narasimhachari and Landa 1991) . Blood levels of amitriptyline and imipra mine and their demethylated metabolites vary widely (Muscettola et al. 1978; Corona et al. 1990; Narasim hachari and Landa, 1991) . Indeed, animal studies showed that acute administration of amitriptyline and imipramine inhibited NE uptake more effectively than 5-HT uptake in vivo (Wong and Bymaster 1976; Fuller and Wong 1987) . We have developed fluoxetine, a selec tive inhibitor of 5-HT uptake, and tomoxetine, a selec tive inhibitor of NE uptake, as potential antidepressant drugs (Wong et al. 1974 (Wong et al. , 1975 (Wong et al. , 1982 . Fluoxetine is now available in many countries for the treatment of depres sion (BenfIeld et al. 1986; Beasley et al. 1990 ), while a preliminary study suggested that tomoxetine might have antidepressant activity (Chouinard et al. 1984) . In this article, we report that LY248686 (a positive isomer; vitro and in vivo. Because of its pharmacological proftle, L Y248686 may be a potentially useful antidepressant drug that can inhibit both 5-HT and NE uptake, lead ing to simultaneous increases of 5-HT and NE trans mission. Moreover, because of its ability to suppress food intake in rats, LY248686 might have a low propen sity to cause weight gain, a common side effect of tricy clic antidepressant drugs.
MATERIALS AND METHODS

Monoamine Uptake In Vitro
Sprague-Dawley rats in groups of 10 animals (100 to 150 g; Harlan Industries, Cumberland, IN) were housed in a room with a 12-hour darkllight cycle (lights on at 0600) at 23°C and had free access to Purina rat chow pellets and water. Rats were killed by decapitation. Whole brains were removed and brain areas were im mediately dissected. Cerebral cortex, hypothalamus, or striatum was homogenized in nine volumes of a medium containing 0.32 mollL sucrose and 20 mmollL glucose. Crude synaptosomal preparations were iso lated after differential centrifugation at 1,000 g for 10 minutes and 17,000 g for 28 minutes. The fmal pellets NO. 1 were suspended in the same medium and kept on ice until used within the same day. Synaptosomal uptake of 3H-5-HT, 3H-NE or 3 H_ dopamine eH-DA) was determined as follows: synap tosomal preparations (equivalent to 0.5 to 1 mg protein) were incubated at 37°C for 5 minutes in 1 ml of Krebs· bicarbonate medium containing 10 mmollL glucose, 0.1 mmollL iproniazid, 1 mmollL ascorbic acid, 0.17 mollL ethylene-diamine tetraacetic acid (EDTA), 3H-mono amine at a specifted concentration, and compounds at 5 or more concentrations. The reaction mixture was im· mediately diluted with 2 ml 0.9% saline and ftltered, using Whatman GF/B fIlters, under vacuum with a cell harvester (Brandel, Gaithersburg, MD) . Filters were rinsed twice with approximately 5 ml ice-chilled 0.9% saline and were transferred to a counting vial contain· ing 10 ml scintillation fluid (PCS; Amersham, Arling ton Heights, IL). Radioactivity was measured by a liq uid scintillation spectrophotometer. Accumulation of radioactivity at 4°C represented the background and was subtracted from all samples.
The uptake of 3H-5-HT into human platelets was assessed using a modiftcation of the published method (Horng and Wong 1976) . Blood (40 ml) was drawn from a healthy human volunteer into a syringe containing 4 ml 3.8% sodium,citrate in normal saline, pH 7.4. Af· ter the addition of another 4 ml normal saline, the blood was centrifuged at 100 g for 15 minutes at room tern· perature. The resulting top layer of platelet-rich plasma was recovered, an aliquot taken for platelet concentra· tion determination, and the remainder stored on ice un· til use, within 2 hours. The platelet-rich plasma was then diluted to a concentration of 126 x 103 plate lets/microliter, and a O.l-ml aliquot was mixed with 2 ml Krebs-bicarbonate buffer, pH 7.4, containing 10 mmollL glucose, 0.1 mmollL iproniazid, 1 mmollL ascorbic acid, 0.17 mmollL EDT A, and 21 J.l.1 of ead drug, respectively, resulting in a reaction medium con· taining 1.26 x 107 platelets and 50 nmollL 3H-5-HT. Triplicate samples were incubated at 37°C for 3 minutes; 0.1 ml 20% formaldehyde was then quickly added to each tube to terminate the reaction. Platelets were har· vested by ftltration through Whatman GF/B ftlters using a cell harvester. Radioactivity on the ftlter was measured by liquid scintillation. Radioactivity in platelets in· cubated at 4°C represents nonspeciftc uptake. Inhibi tor constants (Ki values)' were calculated from ICsi values (concentrations that inhibit 50% of 3H-mono amine uptake of radioligand binding) according to the method of Cheng and Prusoff (1973) .
Inhibition of Monoamine Uptake In Vivo
For in vivo studies, rats (fIve animals per group) were fasted overnight before oral administration of drugs. Alternatively, rats (fIve animals per group) fed ad libi· tum were given drugs by the specifIed routes and doses. Rats were killed by decapitation 1 hour after drug treat ment or at the specifIed time intervals. Brains were quickly removed, dissected, and placed either in cold 0.32 mollL sucrose medium for uptake studies or were frozen , on dry ice for determinations of monoamine and metabolite levels. In uptake studies, the hypothalamus was homogenized in 0.6 rnl medium, striatum from the right side in 1 ml medium, and one-half cortex in 5 rnl medium; this yielded 0.5 to 1.0 mg protein per 0.1 ml.
The uptake of 14C-NE in rat heart was determined by a modifIcation of the method of Hertting et al. (1961) . Drugs were administered 30 minutes before intrave nous administration of 11lCi 14C-NE. After 15 minutes, the rats were killed by decapitation and the hearts were removed, opened, blotted, and frozen on dry ice. After digestion in 1 rnl heated 9:1 (vall vol) 30% H202/70% perchloric acid, 10 rnl scintillation fluid was added and radioactivity was determined by liquid scintillation spectrometery .
HPLC Procedure to Measure Metabolites
For measurement of monoamines and metabolites, brain tissues were homogenized in 5 to 10 volumes of 0.1 N trichloroacetic acid containing internal standard (5-hydroxyindolecarboxylic acid) and then centrifuged at 10,000 g for 10 minutes. The monoamines and me tabolites in 20 III supernatant were separated by HPLC and measured by electrochemical detection. The ana lytical column was a 150 x 4.6-mm C18-5, micron reverse-phase column (Alltech, Deerfield, IL) heated to 40°C. The mobile phase, containing 0.1 moliL monochloroacetic acid, pH 2.6, 0.5 rnmollL EDTA, 7.5% acetonitrile, and 150 mg/l of Na octylsulfonate, was pumped at 1 rnl/min. Internal standards -homovanillic acid, 5-HIAA (5-hydroxyindole acetic acid), and 5-HT, respectively-were eluated and determined ampero metrically using a glassy carbon electrode at 0.83 volts Ag/AgCl. Peak heights were measured and corrected using the internal standard, and quantities were calcu lated by comparing to a standard curve.
Radiolabe led Ligand Binding in Brain Membrane Preparations
The synaptosomal preparation of rat cerebral cortex or bovine striatum was suspended by homogenizing in 50 volumes of cold reaction medium (50 mmoliL Tris, 150 rnmoliL NaCl, 50 mmollL KCl, pH 7.4) and cen trifuging at 50,000 g for 10 minutes. The process was repeated two times with a 10-minute incubation at 37°C between the second and third washes. The resulting pellet was stored at -70°C until use.
Binding of 3H-paroxetine to 5-HT uptake sites was carried out in 2 rnl reaction medium containing the 5-HT and NE Uptake Inhibitor 25 appropriate drug concentration, 0.1 nmollL 3H-parox etine, and the cerebral cortical membrane (50 Ilg pro tein/tube) (Marcus son et al. 1988) , while 3H-tomoxe tine at 0.2 nmollL was used to label NE uptake sites using a higher concentration of 300 mmollL NaCl, as previously described (Wong et al. 1991) . Samples were incubated at 37°C for 30 minutes; those containing 1 IlmoliL fluoxetine or desipramine were used to de termine nonspecific binding of 3H-paroxetine and 3H-tomoxetine, respectively. After incubation, the tubes were fIltered through Whatman GF/B fIlters, which were soaked in 0.05% polyethylenimine for 1 hour before use, using a cell harvester by adding about 4 rnl cold Tris buffer (pH 7.4), aspirating, and rinsing the tubes three additional times. Filters were then placed in scintillation vials containing 10 rnl scintilla tion fluid, and the radioactivity was measured by liq uid scintillation spectrophotometry.
Radioligand binding to various receptors of neu rotransmitters was measured by the established proce dures as listed in Table 1 .
Food Intake Studies
Male Sprague-Dawley rats (250 g; three or six animals per group) were meal-fed Purina rat chow and allowed water ad libitum for at least 3 days in our laboratory before being used in the study. Rats were then fasted for 42 hours. Inhibitors of monoamine uptake were ad ministered at the specifIed doses 30 minutes before feed ing. Food intake was recorded by weighing the pellets and spillage at the beginning and end of the indicated periods of time.
LY248686, ( + )-N-methyl-3-(1-naphthalenyloxy)-2-thiophenepropanamine, ethandioate, its negative iso mer (L Y248685), and its racemic mixture (L Y227942) Statistical analysis was conducted by the use of Stu dent's t test to compare means of control and drug treated samples. Probability less than 0.05 was regarded as signifIcant. 
R, Rat; B, bovine.
RESULTS
In Vitro Inhibition of Uptake L Y248686 inhibited 5-HT uptake in synaptosomal preparations of hypothalamus ( Fig. 2A ) most potently, with an ICso of 2.6 ± 0.4 nmollL, followed by the nega- Gozlan et al. 1983 Doods et al. 1985 Hoyer et al. 1985 Heuring and Peroutka 1987 Leysen et al. 1982 Wong et al. 1983 Wong et al. 1983 Wong et al. 1983 Wong et al. 1983 Wong et al. 1983 Wong et al. 1983 tive isomer (L Y248685) and fluoxetine, with ICso values of 5.3 ± 0.9 and 22.4 ± 3.6 nmollL, respectively. Tomox etine and amitriptyline were weaker, with ICso values of 99.3 ± 16.3 and 106.2 ± 16.6 nmollL, respectively. Both L Y248686 and its negative isomer inhibited NE up take in hypothalamic synaptosomes ( Fig. 2B ) with about equal potencies, as indicated by their ICso values of 7.0 ± 0.8 and 6.0 ± 0.7 nmollL, respectively. As reported previously (Wong et al. 1982) , tomoxetine (LY139603) potently inhibited NE uptake effectively, with an ICso of 1.9 ± 0.2 nmollL, while amitriptyline was moder ately potent, with an ICso of 34.8 ± 4.0 nmollL, and fluoxetine was least potent, with an ICso of 517.5 ± 56.9 nmollL.
CA) Inhibition of Serotonin Uptake
The uptake of 5-HT in cortical synaptosomes was inhibited by the two optical isomers and the dextrorota tory isomer was slightly more potent, as indicated by their inhibitor constants (Ki values; Table 2 ). Both isomers were about equipotent as inhibitors of NE up take in cortical synaptosomes ( Table 2 ). The dextrorota tory and levorotatory isomers inhibited DA uptake in striatal synaptosomes at concentrations 80 and 75 times higher than the Ki concentrations needed to inhibit 5-HT uptake, and 24 and 41 times higher than the Ki concentrations needed to inhibit NE uptake.
Uptake of 5-HT in human platelets was potently inhibited by both isomers (Table 2) . Again, LY248686 was slightly more potent than LY248685, as indicated by their Ki values. L Y248686 inhibited the sodium-dependent binding of 3H-paroxetine (Marcus son et al. 1988 ) and 3H_ tomoxetine (Wong et al. 1991) to uptake carriers of 5-HT and NE, with Ki values of 0.53 ± 0.10 and 2.1 ± 1.1 nmollL, respectively ( Table 2) . The negative isomer, LY248685, was slightly less potent than L Y248686 in blocking 3H-paroxetine binding.
In Vivo Inhibition of Uptake
In hypothalamic homogenates of rats treated with LY248686 oxalate at 5, 10, and 20 mg/kg PO, 5-HT and Synaptosomal preparations (equivalent to 1 mg protein) isolated from cerebral cortex were incubated in triplicate samples at 37°C for 3 minutes in Krebs bicarbonate (saturated with 95% 02 and 5% C02), pH 7.4, containing 10 mmollL glucose, 0.1 nmollL iproniazid, 0.2 mg/ml ascorbic acid, 0.2 mmollL EDTA, 0.051lmollL [ 3 H)-5-HT or [ 3 H)-NE and an uptake inhibitor at five or more concentrations. Up take of [ 3 H)-DA was conducted in striatal preparations. 3 H-Paroxetine and 3 H-tomoxetine binding studies in cortical membranes and 3 H-5-HT uptake in human blood platelets were conducted as described in Materials and Methods. Values (mean ± SE) were obtained from three or more separate determinations. The inhibitor constants (Ki values) were calculated from rC50 values according to the method of Cheng and Prusoff (1973) .
NE uptake were signifIcantly inhibited within 1 hour of administration (Fig. 3) . The inhibitory effects on up take of both monoamines were dose dependent. The mean values of the half-effective doses (ED5o in micro moles/kilogram, Table 3 ) of L Y248686 were slightly lower than that of L Y248685 for the inhibition of 5-HT uptake, while the ED50 values of the two isomers for the inhibition of NE uptake were similar ( Table 3) . LY248686 was approximately fIve times more potent by the subcutaneous route than by the oral route of ad ministration as an inhibitor of 5-HT and NE uptake ex vivo. Dopamine uptake in striatal homogenates was not aff ected on administration of either isomer up to 103 "mol/kg PO (Table 3) .
Thus, L Y248686 in vitro and in vivo was consis tently found to be slightly more potent than its levorota tory iso mer, LY248685, in blocking 5-HT uptake in syn aptoso mal preparations of hypothalamus and cerebral cortex. Moreover, LY248686 was slightly more potent as a 5-HT uptake inhibitor as judged by in vitro 5-HT uptake in human platelets and binding of 3H-parox etine to the 5-HT uptake carrier. Based on these fmdings, L Y248686 was selected over L Y248685 for fur ther studies.
Three days after a single administration of p-chloro amphetamine (p-CA) at 10 mg/kg IP, 5-HT uptake in homogenates of cerebral cortex was signifIcantly re duced to 39% of control (Table 4) . Pretreatment with LY248686 at 26, 52, 92, and 129 J.lmollkg IP dose depen dently prevented the decrease of 5-HT uptake caused by p-CA treatment. The ED50 of L Y248686 was calcu lated to be 90 J.lmollkg IP. The concentrations of 5-HT and its metabolite, 5-HIAA, in hypothalamus were significantly reduced by p-CA treatment, which was partiall y prevented by the highest dose of L Y248686 (Ta ble 4).
When L Y248686 was administered twice at a dose Figure 3. Dose-dependent inhibition of 5-HT and NE up take in rat hypothalamus by LY248686 ex vivo. Rats (five per group) that had been fasted for 24 hours were treated with 5, 10, or 20 mg/kg LY248686 oxalate PO one hour before sacrifice. The control group was treated with saline. Aliquots of hypothalamic homogenates were incubated in duplicate samples at 37°C for 5 minutes in the same Krebs bicarbonate medium as described in Figure 2 , except that both 0.051lmo1lL 3H-5-HT and O.lllmollL 14C-NE were included. Accumula tion of radioactivity at 4°C was subtracted at each dose of up take inhibitor. Other conditions were as described in Materials and Methods. Significant diff erences between treated groups and respective control groups are indicated as follows: a, p < 0.005; b, P < 0.05. Vertical bars represent ±SE of the mean percent inhibition. Rats (flve per group) were treated for one hour with either vehi cle or an uptake inhibitor at 5, 10, and 20 mg/kg (13, 26, and 52 J-lmoIlkg, respectively) orally in three separate determinations, or at 0.2, 0.5, 1, 5, and 10 mg/kg (0.5, 1.3, 2.6, 13 and 26 J-lmollkg, respec tively) subcutaneously in one determination. Uptake activities of 3H-5-HT and 14 C_NE in homogenate of individual hypothalamus in duplicate samples were determined. Uptake of 3 H-DA was deter mined in striatal homogenates of individual rats treated with L Y248686 or L Y248685 at 50 mg/kg (103 J-lmollkg) PO an hour be fore sacriflce. Determinations of uptake of the radioactive mono amines were conducted under conditions as described in Table 2 . Value (mean ± SE) was derived from three separate determinations.
of 13,26, or 52 �mol/kg IP 30 minutes before and 7.5 hours after injection of p-CA, the effects of p-CA on 5-HT uptake were completely blocked ( Table 5 ). The blockade of the p-CA-induced depletion of 5-HT and 5-HIAA by the repeated injection of L Y248686 at all three doses was partial, but without statistical signifIcance.
Oral administration of L Y248686 at 26 and 52 �mol/kg PO reduced the accumulation of radioactive NE in rat hearts to 70% and 37% of control, respectively, although only the effect at the higher dose was statisti cally signifIcant (Table 6 ). Thus, the oral potencies of L Y248686 in blocking NE uptake in heart and in brain ex vivo (Table 3) are comparable.
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Duration of Uptake Inhibition In Vivo
After a single administration of L Y248686 at 52 �mol/kg PO, rats were killed at time intervals of 1, 3, 6, and 16 hours. The activities of 5-HT and NE uptake in hypotha lamic homogenates of the drug-treated groups were signifIcantly reduced 1 to 6 hours after treatment com pared with saline-treated control rats (Fig. 4) . The ratio of 5-HT and NE uptake inhibition remained constant throughout the 6-hour period. The activities of 5-HT and NE uptake returned to control levels by 16 hours after administration of LY248686.
Food Intake Studies
As a selective inhibitor of 5-HT uptake, fluoxetine is known to suppress food intake in laboratory animals (Goudie et al. 1976; Wong et al. 1988) . In rats deprived of food for 42 hours, LY248686 was as effective as fluox etine in the suppression of food intake during 1 and 4 hours of food access (Table 7) . At twice the dose of LY248686, nisoxetine, a selective inhibitor of NE up take, suppressed feeding only during the fIrst hour of food access. In a separate experiment, a dose dependent suppression of food intake by L Y248686 was demonstrated (Table 7) during both periods of food in take measurement. Coadministration of L Y248686 and the 5-HT precursor, 5-hydroxytryptophan (5-HTP), which at a dose of 10 mg/kg (45 �mol/kg) did not pro duce signifIcant effects on feeding, produced a more profound suppression of food intake in both periods of measurement. The estimated ED50 doses of L Y248686 during 1 and 4 hours of food access were 13.1 and 36.3 �mol/kg, respectively, and were reduced to 4.0 and 10.8 �mol/kg, respectively, on combination with 5-HTP.
In radioreceptor assays, L Y248686 inhibited ra- 2.7 ± 0.0 1.4 ± 0.1* 1.4 ± 0.1* 1.5 ± 0.0* 1.7 ± 0.0* 1.9 ± 0.9* t 5-HIAA 1.7 ± 0.1 0.9 ± 0.0* 0.9 ± 0.0* 0.9 ± 0.0* 1.0 ± 0.0* 1.2 ± O.l* t Rats (flve per group) were treated IP with vehicle or LY248686 at the specifled doses a half hour before injection of 10 mg/kg IP of p-CA. Rats were killed 3 days later and 5-HT uptake in cerebral cortex homogenates and levels of indoles were measured as described in Materials and Methods.
* Signiflcantly different from control group (p < 0.05). t Signiflcantly different from p-CA-treated group (p < 0.05). 14C-NE Heart Uptake (dpm/milligram heart) 5720 ± 811 7100 ± 589 4054 ± 291 2106 ± 725* Rats (ftve per group) were treated orally with saline vehicle or LY248686 at the indicated doses; a half hour later, 1 J,lCi of 14 C-NE was injected IV. Rats were killed 15 minutes later, and the uptake into heart was determined as described in Materials and Methods.
• Signiftcantly different from control group (p < 0.05). NEUROPSYCHOPHARMACOLOGY 1993-VOL. 8, NO.1 0.01 ± 0.01* 0.32 ± 0.14* Rats (six in Group A and three in Group B) deprived of food for 42 hours were treated with saline, L Y248686, fiuoxetine, nisoxetine or 5-hydroxytryptophan (5-HTP) at the specifIed dose a half hour before food access.
Statistically signifIcant diff erences between saline and drug-treated groups: * p < 0.001; t p < 0.005; :j: p < 0.025.
an inhibitor of 5-HT uptake than NE uptake in vitro are not translated into in vivo differences, as indicated by the similar E050 values.
p-Chloroamphetarnine and 6-0HDA appear to use the uptake carriers of 5-HT and NE, respectively, to en ter the corresponding nerve terminals before initiation of depletion of the monoamines and decreases of up take activities due to neurotoxicity (Evetts and Iversen 1970; Meek et al. 1971; . Fluoxe tine, a selective inhibitor of 5-HT uptake, blocks only the p-CA-induced depletion of 5-HT, with an E050 of 1.21lmollkg IP , while tomoxe tine, a selective inhibitor of NE uptake, blocks only the 6-0HOA-induced depletion of NE in heart with an E050 of 5.8llmollkg IP . In this 14,000 18,000 study LY248686 also prevents the decrease of brain 5-HT uptake caused by treatment with p-CA, with an EDso dose of 90 Ilmollkg IP; L Y248686 lowers uptake of NE in heart in vivo and in hypothalamic homogenate ex vivo with comparable potencies. In previous studies, amitriptyline at 159 Ilmollkg IP gave only 32% protec· tion from the decrease of 5-HT uptake caused by p-CA treatment and 50% protection from the decrease of NE uptake caused by 6-hydroxydopamine treatment (Wong and Bymaster 1976) . The apparent lower poten cies of L Y248686 and amitriptyline as antagonists of the p-CA-induced decrease of 5-HT uptake is probably due to the shorter durations of action of these uptake in hibitors than that of p-CA . Indeed, antagonism of the p-CA-induced decreases of 5-HT up take was rendered more complete by administering half of the dose of LY248686 twice, i.e., 30 minutes before and 7. 5 hours after p-CA treatment. The E050 was re duced from 90 to less than 13 x 2 Ilmollkg IP (Tables  4 and 5 ), a dose intermediate between the E050 deter mined by subcutaneous and oral routes of administra tion (Table 3) . Moreover, the concomitant inhibition of 5-HT and NE uptake by L Y248686 after a single administration persists for as long as 6 hours, which is comparable to the duration of lowering NE uptake by tomoxetine ex vivo (Wong et al. 1982) but shorter than the duration of 24-hour inhibition of 5-HT uptake by fluoxetine (Wong et al. 1975) . Amitriptyline, however, after a sin gle administration of 20 mg/kg SC, failed to lower 5-HT uptake, but did lower NE uptake within 1 and 6 hours to 35% and 48% of the control activities, respectively (data not shown). LY248686 at doses that blocked uptake of 5-HT and NE ex vivo effectively suppressed feeding of food deprived rats. The synergistic effect of 5-HTP, a precur sor amino acid of 5-HT, supports the notion that the anorectic effects depend on synaptic supply of 5-HT, which as a neurotransmitter exerts an inhibitory role on feeding behavior (Blundell 1977; Wong and Fuller 1987) . The present studies show that L Y248686 treat ment up to 4 hours (Table 7) is at least as effective as fiuoxetine, which has been demonstrated to suppress food intake of various feeding paradigms in normal and genetically obese rodents (Wong et al. 1988; Fuller and Wong, 1989) . In a similar feeding paradigm, amitripty line or imipramine at doses up to 10 mg/kg (32 �mollkg) IP failed to suppress food intake in rats after food depri vation (data not shown). On the other hand, con comitant inhibition of NE uptake has not negated the appetite-suppressive effects of L Y248686, although a-adrenergic stimulation is known to increase feeding (Weiss et al. 1986) . Moreover, as a potential antidepres sant drug, L Y248686 would be anticipated to have a low propensity to cause weight gain.
In addition, animal studies show that L Y248686 pro duced other pharmacological responses consistent with its action as an inhibitor of 5-HT and NE uptake Wong et al. 1985 Wong et al. , 1988 Wong et al. , 1990 . At doses effectively inhibiting 5-HT uptake in vivo, LY248686 lowers alcohol intake in high-alcohol-drinking rats (Murphy et al. 1989) , potentiates the analgesic effects of morphine in mouse writhing tests (J.D. Leander, per sonal communication; Hynes and Fuller 1982) , and potentiates the tremor and head twitch induced by 5-HTP (J. D. Leander, personal communication; Hwang and VanWoert 1980) . Thus, the ability of L Y248686 to inhibit NE uptake does not have a negative influence on its ability to promote serotonergic functions. Because of the weak affinity for subtypes of 5-HT receptors, the pharmacological responses are not likely to be medi ated by direct interaction between the uptake inhibitor and the 5-HT receptors examined. On the other hand, as demonstrated with other inhibitors of NE uptake, L Y248686 blocks the hypothermic effects of apomor phine (J.D. Leander, personal communication; Menon et al. 1984) , and potentiates the analgesic effect of cloni dine in the mouse writhing tests (J. D. Leander, personal communication; Hynes and Henderson 1984) .
Down-regulation of J3-adrenergic receptors after long-term administration of tricyclic antidepressant drugs (Frazer et al. 1974; Banerjee et al. 1977 ) and elec troconvulsive shock (Bergstrom and Kellar, 1977) may depend not only on the input from NE neurons (Wolfe et al. 1978) , but also on 5-HT innervation (Brunello et al. 1982; Janowsky et al. 1982) . Since selective lesions 5-HT and NE Uptake Inhibitor 31 of 5-HT terminals with 5,7-dihydroxytryptamine, but not merely inhibition of 5-HT synthesis by p-chloro phenylalanine, prevent down-regulation of J3-adren ergic receptors by antidepressant treatments, a factor present in 5-HT terminals other than 5-HT itself may be involved (Nimgaonkar et al. 1985) . The combined chronic administration of desipramine and fluoxetine appears to produce a rapid down-regulation of rat cor tical J3-adrenergic receptors (Dudley and Baron 1989) . Thus, there appear to be cooperative interactions be tween the NE and 5-HT neurotransmission systems.
A persistent inhibitor of 5-HT and NE uptake such as LY248686 might facilitate the adaptive changes in J3-ad renergic receptors as a consequence of a concerted aug mentation of the 5-HT and NE neurotransmission systems.
The transporters of 5-HT and NE have been useful biochemical and pharmacological targets for the devel opment of antidepressant drugs. Fluoxetine, a selec tive inhibitor of 5-HT uptake, has ample evidence for its antidepressive efficacy (Bentteld et al. 1986; Beasley et al. 1990) , while tomoxetine, a selective inhibitor of NE uptake, might also have antidepressant effects (Chouinard et al. 1984) . Other selective inhibitors of 5-HT uptake, including citalopram (Dufour et al. 1987) , indalpine (Shopsin et al. 1983 ) and sertraline (Doogan and Caillard 1988) , also possess antidepressive efficacy. LY248686, a member of the naphthalenyloxythiophene propanamine series, being endowed with the ability to inhibit the uptake of 5-HT and NE concomitantly, may have therapeutic potential in the treatment of depres sion. Indeed, a preliminary study of the combination of fluoxetine and desipramine suggests a more rapid onset of antidepressant effect (Nelson et al. 1991) .
The tricyclic antidepressant drugs (Wernicke et al. 1987) appear to produce side effects by antagonizing the central as well as peripheral muscarinic-acetylcho line receptors, histamine-H1 receptors, and a-adren ergic receptors (Richelson and Nelson 1984) . Because of their low affinity for these neuronal receptors, fluox etine and its congeners tend to produce fewer side effects (Wernicke et al. 1987) . With relatively weak affinity for the neuronal receptors examined, L Y248686 might have a lower propensity to produce a prottle of side effects generally associated with the tricyclic an tidepressant drugs. Moreover, because of its ability to suppress food intake, LY248686 may have a low propen sity to stimulate weight gain during treatment of depression.
In summary, we have described the biochemical pharmacology of L Y248686, a potent inhibitor of 5-HT and NE uptake. LY248686 may be a useful pharmaco logical tool to determine if the simultaneous facilitation of 5-HT and NE neurotransmission provides advan tages relative to compounds that affect only one of these neurotransmitter systems. Moreover, LY248686 exhibits the pharmacological profile of a potential antidepres sant drug.
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